Literature DB >> 27903600

Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method.

Kenneth P Smith1, Thea Brennan-Krohn1,2, Susan Weir1, James E Kirby3.   

Abstract

Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae generally cannot be treated with penicillins and cephalosporins. However, some later-generation cephalosporins, including cefepime, are poorly hydrolyzed by specific ESBL enzymes, and certain strains demonstrate in vitro susceptibility to these agents, potentially affording additional treatment opportunities. Moreover, the ability to adjust both the dose and dosing interval of beta-lactam agents allows the treatment of strains with elevated MICs that were formerly classified in the intermediate range. The ability to treat strains with elevated cefepime MICs is codified in new susceptible dose-dependent (SDD) breakpoints promulgated by the Clinical and Laboratory Standards Institute. In the interest of validating and implementing new cefepime SDD criteria, we evaluated the performances of Vitek 2, disk diffusion, and a MicroScan panel compared to that of reference broth microdilution (BMD) during the testing of 64 strains enriched for presumptive ESBL phenotype (based on nonsusceptibility to ceftriaxone). Surprisingly, categorical agreement with BMD was only 47.6%, 57.1%, and 44.6% for the three methods, respectively. Given these findings, we tested the performance of the HP D300 inkjet-assisted broth microdilution digital dispensing method (DDM), which was previously described by our group as an at-will testing alternative. In contrast to commercial methods, DDM results correlated well with the reference method, with 86% categorical agreement, 91.1% evaluable essential agreement, and no major or very major errors. The reproducibility and accuracy of MIC determinations were statistically equivalent to BMD. Our results provide support for the use of the DDM as a BMD equivalent methodology that will enable hospital-based clinical laboratories to support cefepime MIC-based dosing strategies.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ESBL; antimicrobial susceptibility testing; broth microdilution; cefepime; digital dispensing; extended-spectrum beta-lactamase producer; inkjet; susceptibility testing; susceptible dose dependent; verification

Mesh:

Substances:

Year:  2016        PMID: 27903600      PMCID: PMC5277516          DOI: 10.1128/JCM.02128-16

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

Review 1.  Defining an extended-spectrum beta-lactamase.

Authors:  D M Livermore
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067

2.  Emergence of extended-spectrum beta-lactamase-producing Escherichia coli in community hospitals throughout North Carolina: a harbinger of a wider problem in the United States?

Authors:  Joshua T Freeman; Daniel J Sexton; Deverick J Anderson
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

3.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.

Authors:  Mitchell J Schwaber; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-09-11       Impact factor: 5.790

4.  Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.

Authors:  Woori Jang; Yeon-Joon Park; Kang Gyun Park; Jinkyung Yu
Journal:  J Antimicrob Chemother       Date:  2013-05-12       Impact factor: 5.790

Review 5.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

6.  Risk factors associated with extended-spectrum beta-lactamase-producing organisms at a tertiary care hospital.

Authors:  Eileen M Graffunder; Karen E Preston; Ann M Evans; Richard A Venezia
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

Review 7.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

8.  Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.

Authors:  J Fung-Tomc; T J Dougherty; F J DeOrio; V Simich-Jacobson; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

9.  Increasing Incidence of Extended-Spectrum β-Lactamase-Producing Escherichia coli in Community Hospitals throughout the Southeastern United States.

Authors:  Joshua T Thaden; Vance G Fowler; Daniel J Sexton; Deverick J Anderson
Journal:  Infect Control Hosp Epidemiol       Date:  2015-10-13       Impact factor: 3.254

10.  Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000).

Authors:  Ronald N Jones; Douglas J Biedenbach; Ana C Gales
Journal:  Int J Antimicrob Agents       Date:  2003-01       Impact factor: 5.283

View more
  8 in total

1.  The Poisoned Well: Enhancing the Predictive Value of Antimicrobial Susceptibility Testing in the Era of Multidrug Resistance.

Authors:  Thea Brennan-Krohn; Kenneth P Smith; James E Kirby
Journal:  J Clin Microbiol       Date:  2017-05-03       Impact factor: 5.948

2.  The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination.

Authors:  Kenneth P Smith; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

3.  Synergistic Activity of Colistin-Containing Combinations against Colistin-Resistant Enterobacteriaceae.

Authors:  Thea Brennan-Krohn; Alejandro Pironti; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

4.  Reply to Humphries and Simner, "Verification Is an Integral Part of Antimicrobial Susceptibility Test Quality Assurance," and Wojewoda et al., "College of American Pathologists (CAP) Microbiology Committee Perspective: the Need for Verification Studies".

Authors:  James E Kirby; Thea Brennan-Krohn; Kenneth P Smith
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

5.  Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology.

Authors:  Thea Brennan-Krohn; Katherine A Truelson; Kenneth P Smith; James E Kirby
Journal:  J Antimicrob Chemother       Date:  2017-10-01       Impact factor: 5.790

6.  Development of MAST: A Microscopy-Based Antimicrobial Susceptibility Testing Platform.

Authors:  Kenneth P Smith; David L Richmond; Thea Brennan-Krohn; Hunter L Elliott; James E Kirby
Journal:  SLAS Technol       Date:  2017-08-24       Impact factor: 3.047

7.  Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa-the EM200 study.

Authors:  J Belkhair; S Nachat; S Rouhi; H Ouassif; S Abbassi; N Soraa
Journal:  New Microbes New Infect       Date:  2021-03-19

Review 8.  We Cannot Do It Alone: The Intersection of Public Health, Public Policy, and Clinical Microbiology.

Authors:  Rose A Lee; James E Kirby
Journal:  Clin Lab Med       Date:  2019-07-06       Impact factor: 1.935

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.